All In Biotech

NDA 008316 · Sanofi Aventis US

Primaquine

Primaquine Phosphate · Oral

Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1952

Jan 23, 1952

Approved uses

1

Original approval plus efficacy supplements

Registered trials

124

31 Phase 3, 7 recruiting

FAERS reports

87

76 serious, 6 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 11, 2026.

INDICATIONS AND USAGE Primaquine phosphate Tablets are indicated for the radical cure (prevention of relapse) of vivax malaria.

Mechanism: Mechanism of Action Primaquine phosphate is an 8-aminoquinoline antimalarial drug. The mechanism of action has not been fully established. The major assumptions are an inhibition of the mitochondrial system of dormant parasites, and an oxidative stress generated through reactive metabolites in infected cells. In humans, primaquine phosphate activity is probably related to hydroxylated metabolites generated intrahepatically by CYP2D6.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 23, 1952 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • PRIMAQUINE · PRIMAQUINE PHOSPHATE EQ 15MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Primaquine" as an intervention, any sponsor and status, largest first.

All 124 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • methaemoglobinaemia20
  • drug ineffective13
  • drug interaction12
  • pyrexia10
  • cyanosis8
  • plasmodium vivax infection7
  • chromaturia6
  • dyspnoea6
  • off label use6
  • drug eruption5
  • headache5
  • hyponatraemia4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20051
20101
20123
20137
20142
20153
20162
20173
20185
20197
20201
202133
20229
20231
20265

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Primaquine (Primaquine Phosphate)

2024 spending

$27K

Beneficiaries

336

470 claims

Per beneficiary

$79

$1.41 per unit

View as table
YearSpending
2020$13,854
2021$13,434
2022$18,535
2023$26,191
2024$26,597

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 322 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.